atovaquone

atovaquone is a synthetic hydroxynaphthoquinone antimicrobial medication primarily used for the prevention and treatment of specific protozoan infections. It is a key component in the fixed-dose combination drug Malarone, used against falciparum malaria, and is also employed as a second-line agent for treating Pneumocystis jirovecii pneumonia. The drug functions by selectively inhibiting mitochondrial electron transport in susceptible parasites, disrupting crucial cellular energy production.

Medical uses

Atovaquone is indicated for several specific infectious diseases. Its primary use is in the prophylaxis and treatment of acute, uncomplicated malaria caused by Plasmodium falciparum, almost always in combination with proguanil as the product Malarone. This combination is recommended by bodies like the Centers for Disease Control and Prevention for travelers to regions with chloroquine-resistant strains. It is also approved for the treatment of mild to moderate Pneumocystis jirovecii pneumonia in patients who are intolerant to trimethoprim/sulfamethoxazole. Additionally, it is used as an alternative therapy for toxoplasmosis, particularly in individuals with HIV/AIDS who cannot tolerate standard regimens like pyrimethamine combined with sulfadiazine.

Adverse effects

The adverse effect profile of atovaquone is generally considered milder than that of many alternative antimicrobials. Common side effects include headache, insomnia, dizziness, nausea, vomiting, diarrhea, and abdominal pain. Rash and pruritus are also frequently reported. Elevated levels of liver enzymes and jaundice have been observed, necessitating monitoring in patients with pre-existing hepatic impairment. Serious but rare adverse reactions include Stevens–Johnson syndrome, anaphylaxis, and severe neutropenia. Gastrointestinal side effects can significantly reduce drug absorption, potentially leading to therapeutic failure.

Pharmacology

The pharmacological action of atovaquone is centered on its disruption of mitochondrial function in target pathogens. It acts as a potent inhibitor of the mitochondrial electron transport chain at the bc1 complex (Complex III), analogous to its action in the Plasmodium apicoplast. This blockade collapses the mitochondrial membrane potential, halting pyrimidine biosynthesis and cellular ATP production, which is lethal to the parasite. Pharmacokinetically, it is highly lipophilic and exhibits poor, variable oral bioavailability unless administered with a fatty meal, which can increase absorption by up to three-fold. It is extensively protein-bound (>99.9%) and is not significantly metabolized by the cytochrome P450 system, being excreted unchanged in feces.

History

The development of atovaquone originated from research into hydroxynaphthoquinone compounds at the Wellcome Foundation in the 1970s and 1980s. Scientists were investigating analogs of lapachol, a natural compound with known antiprotozoal activity. Atovaquone was identified as a promising candidate through extensive screening and optimization for activity against Plasmodium and Pneumocystis species. It received approval from the U.S. Food and Drug Administration in 1992 for the treatment of Pneumocystis pneumonia. Its role expanded significantly with the 2000 approval of the fixed-dose combination Malarone with proguanil, which provided a highly effective and well-tolerated option for malaria, particularly valuable in areas with widespread resistance to drugs like chloroquine and sulfadoxine/pyrimethamine.

Society and culture

Atovaquone is marketed under various trade names globally, including Mepron for the monotherapy and Malarone for the combination with proguanil. It is considered an essential medicine by the World Health Organization for its role in malaria management. The drug's high cost has historically been a barrier to widespread use in endemic, resource-limited regions, though generic versions have improved accessibility. Its importance is underscored in protocols from the Infectious Diseases Society of America and the British National Formulary. Research into its potential applications continues, including investigations for use against Babesia species and in combination therapies for resistant toxoplasmosis.

Category:Antimalarial agents Category:World Health Organization essential medicines